Dear healthcare professional,
PO Box 1000 North Wales, PA 19454-1099 Dear Health Care Professional: Merck/Schering-Plough Pharmaceuticals recently announced the primary end point and other results of the ENHANCE trial. You have no doubt seen some of the extensive news coverage generated by our announcement. This has created lots of confusion and questions from health care professionals and patients about VYTORIN®